Evidence map›Paper›PMID 37787446›Full record

ArticleHistology and histopathology2023

The combination of the low immunohistochemical expression of peroxiredoxin 4 and perilipin 2 predicts longer survival in pancreatic ductal adenocarcinoma with peroxiredoxin 4 possibly playing a main role.

Jia Han, Tohru Itoh, Akihiro Shioya, Masaru Sakurai, Takeru Oyama, Motona Kumagai, Hiroyuki Takamura, Masashi Okuro, Tsuyoshi Mukai, Hidekazu Kitakata and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Histology and histopathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Jia Han *Department of Pathology, Kanazawa Medical University Hospital, Ishikawa, Japan. hanjia0227@yahoo.co.jp.
Tohru Itoh *The Director Laboratory, Kanazawa Medical University Hospital, Ishikawa, Japan.
Akihiro ShioyaDepartment of Pathology and Laboratory Medicine, Kanazawa Medical University, Ishikawa, Japan.
Masaru SakuraiDepartment of Social and Environmental Medicine, Kanazawa Medical University, Ishikawa, Japan.
Takeru OyamaDepartment of Pathology and Laboratory Medicine, Kanazawa Medical University, Ishikawa, Japan.
Motona KumagaiDepartment of Pathology, Kanazawa Medical University Hospital, Ishikawa, Japan.
Hiroyuki TakamuraDepartment of Surgical Oncology, Kanazawa Medical University, Ishikawa, Japan.
Masashi OkuroDepartment of Geriatric Medicine, Kanazawa Medical University, Ishikawa, Japan.
Tsuyoshi MukaiDepartment of Gastroenterological Endoscopy, Kanazawa Medical University, Ishikawa, Japan.
Hidekazu KitakataDepartment of Gastroenterological Endoscopy, Kanazawa Medical University, Ishikawa, Japan.
Masaru InagakiDepartment of Surgery, National Hospital Organization, Fukuyama Medical Center, Fukuyama, Japan.
Michiyo HigashiDepartment of Pathology, Field of Oncology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Xin GuoDepartment of Pathology and Laboratory Medicine, Kanazawa Medical University, Ishikawa, Japan.
Sohsuke YamadaDepartment of Pathology and Laboratory Medicine, Kanazawa Medical University, Ishikawa, Japan.
Kanazawa Medical University · JPKanazawa Medical University Hospital · JPFukuyama Cardiovascular Hospital · JPKagoshima University · JP

Funding

Grants-in-Aid for Scientific Research 19K16783Grants-in-Aid for Scientific Research 20K07454
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease with poor prognosis. Therefore, indicators that can be used for the early prediction of the prognosis of PDAC are needed. Peroxiredoxin (PRDX) 4 is a secretion-type antioxidant enzyme located in the cytoplasmic endoplasmic reticulum. Recent studies have reported that it is closely related to the development and prognosis of many types of cancer. Perilipin (PLIN) 2 is a lipid droplet coating protein. The high expression of PLIN2 is known to be an indicator of some types of cancer and oxidative stress management. It is highly suggestive of the interplay between PRDX4 and PLIN2 to some degree. In this study, we collected 101 patients' clinical data and paraffin-embedded specimens with PDAC and analyzed them with immunohistochemical staining of PRDX4 and PLIN2. We found that the low expression of PRDX4 predicts longer survival and a better clinical condition in PDAC patients. Moreover, when the low expression of PRDX4 is combined with the low expression of PLIN2, the 3-year survival is significantly improved. Univariate and multivariate Cox proportional hazard analyses showed that the PRDX4 expression in PDAC was an independent prognostic factor for survival. Taken together, between PRDX4 and PLIN2, PRDX4 plays a main role in prognosis and has the potential to become a clinical prognostic indicator of PDAC.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsPerilipin-2PeroxiredoxinsBiomarkers, TumorHumansPrognosisBiomarkers, TumorPerilipin-2PeroxiredoxinsPRDX4 protein, human

Identifiers

PMID37787446
OpenAlexW4387297214

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.